Syncytial Virus Inhibitor-1 is a potent and orally bioavailable inhibitor of respiratory syncytial virus (RSV) fusion(EC50s of 0.002 μM, 0.004 μM, and 0.002 μM for RSV Long, RSV A2, and RSV B strains, respectively).
JNJ4796 is an oral active fusion inhibitor of the influenza virus, by inhibiting hemagglutinin (HA)-mediated fusion to neutralizing the influenza A group 1 virus. JNJ4796 mimics the functionality of the broadly neutralizing antibodies (bnAbs).
Glycoprotein B is a peptide with the sequence H2N-Ser-Ser-Ile-Glu-Phe-Ala-Arg-Leu-OH, MW= 922.04. glycoprotein B is a viral glycoprotein that is involved in the viral cell entry of Herpes simplex virus. The herpesvirus glycoprotein B is the most highly c
JNJ-2408068 is an inhibitor of respiratory syncytial virus (RSV). JNJ-2408068 exhibited potent antiviral activity with EC50 of 2.1 nM. A similar inhibitory effect was observed in a RSV-mediated cell fusion assay (EC50= 0.9 nM). JNJ-2408068 interferes with
MBX2546 is an Influenza A VirusFusion Inhibitor. MBX2546 binds to HA and inhibits HA-mediated membrane fusion. Both binding and stabilization of HA by MBX2546 are required for the inhibition of viral infection. Mutations in MBX2546-resistant influenza A
RSV-IN-2 is a powerful compound that acts as a dual inhibitor of both wild-type and mutant respiratory syncytial virus (RSV) fusion proteins. It efficiently inhibits the activity of these proteins, with an EC50 value of 0.27 nM for the wild-type and 0.70 nM for the D486N-mutant protein.